In vivo stability of cryoprecipitate fibrinogen.
Because of its lower hepatitis risk, cryoprecipitate has been advocated as a substitute for commercial fibrinogen. Previous literature on cryofibrinogen has demonstrated a short blood t1/2, rendering it unsuitable for therapeutic use. The in vivo clearance of 131I-cryoprecipitate was compared with that of 125I-standard fibrinogen. A small amount of cryoprecipitate was rapidly cleared and apparently was cryofibrinogen. However, the bulk of the cryoprecipitate was cleared with a normal half life, as was cryoprecipitated that was in 10-bag pools. The data indicated cryoprecipitate was an effective in vivo form of fibrinogen and thus the preferred fibrinogen source because of its combining normal t1/2 with single donor procurement.
D011232:Chemical Precipitation; D003080:Cold Temperature; D005340:Fibrinogen / Q000302:isolation & purification / Q000378:metabolism / Q000627:therapeutic use; D006207:Half-Life; D006801:Humans; D007457:Iodine Radioisotopes
D007457:Iodine Radioisotopes; D005340:Fibrinogen